相关实验视频

Updated: Jun 13, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

患者报告的新品牌仿制品特里弗卢诺米德在复发性复发性多发性硬化症的治疗结果

Roya Abolfazli¹, Seyed Massood Nabavi², Amirreza Azimi³

¹Department of Neurology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran,.

Clinical neurology and neurosurgery

|September 13, 2024

概括

品牌通用Teriflunomide在复发性复发性硬化症 (RRMS) 患者中表现出高的患者满意度和坚持. 该研究强调了患者报告的结果在评估疾病修饰疗法 (DMT) 的价值.

科学领域:

药理学和治疗学药理学和治疗学
神经学神经学
患者报告的结果

背景情况:

患者报告的结果 (PRO) 对于了解疾病修饰疗法 (DMT) 对复发性复发性硬化症 (RRMS) 患者的现实影响至关重要.
本研究的重点是评估伊朗患者群体对特定品牌通用Teriflunomide (14毫克片) 的治疗满意度和耐受性.

研究的目的:

在RRMS患者中评估品牌通用Teriflunomide (14 mg) 的患者满意度和耐受性.
为了评估与这种Teriflunomide配方相关的药物坚持和停药率.
通过患者报告的不良事件来调查Teriflunomide的安全性.

主要方法:

一项涉及235名RRMS患者的第四阶段观察性研究,这些患者开始或转换为Teriflunomide每天14毫克.
安全性是主要的终点,患者满意度使用治疗满意度问卷对药物 (TSQM-14) 进行评估.
在18个月的随访期间,对药物坚持和停药率进行了监测.

主要成果:

观察到高达98.1%的药物坚持率.
在18个月的时间里,TSQM-14得分显示了患者满意度的显著改善.
总体中断率为25.96%,主要是由于不良事件 (11%),患者不愿意 (12.7%) 和疾病进展 (4.2%). 常见的不良事件包括皮肤,肝脏和胃肠道问题.

结论:

品牌通用Teriflunomide 14 mg被伊朗RRMS患者接受得很好,有着显著的满意度和高度的坚持.
改善的患者满意度,如TSQM得分所示,表明可能提高DMT的坚持.
患者报告的结果对于评估DMT是有价值的,为临床实践和治疗管理提供了见解.

关键词:

不良事件不良事件患者报告的结果美国TSQM 有关特里弗卢诺胺的

更多相关视频

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...